Item Type | Name |
Concept
|
Growth Inhibitors
|
Concept
|
Fibroblast Growth Factors
|
Concept
|
Insulin-Like Growth Factor I
|
Concept
|
Endothelial Growth Factors
|
Concept
|
Hepatocyte Growth Factor
|
Concept
|
Transforming Growth Factor beta
|
Concept
|
Hematopoietic Cell Growth Factors
|
Concept
|
Receptors, Fibroblast Growth Factor
|
Concept
|
Receptors, Growth Factor
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
Concept
|
Vascular Endothelial Growth Factors
|
Concept
|
Cell Growth Processes
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
Concept
|
Vascular Endothelial Growth Factor A
|
Concept
|
Epidermal Growth Factor
|
Concept
|
Growth Substances
|
Concept
|
Vascular Endothelial Growth Factor Receptor-1
|
Academic Article
|
Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
|
Academic Article
|
The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.
|
Academic Article
|
Hematopoietic growth factors signal through the formation of reactive oxygen species.
|
Academic Article
|
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
|
Academic Article
|
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells.
|
Academic Article
|
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
|
Academic Article
|
Role of the cytoskeletal protein paxillin in oncogenesis.
|
Academic Article
|
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
|
Academic Article
|
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
|
Academic Article
|
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
|
Academic Article
|
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
|
Academic Article
|
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
|
Academic Article
|
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
|
Academic Article
|
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
|
Academic Article
|
Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas.
|
Academic Article
|
c-Met: structure, functions and potential for therapeutic inhibition.
|
Academic Article
|
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
Academic Article
|
Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma.
|
Academic Article
|
The role of ephrins and Eph receptors in cancer.
|
Academic Article
|
Expression and mutational analysis of MET in human solid cancers.
|
Academic Article
|
MET pathway as a therapeutic target.
|
Academic Article
|
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
|
Academic Article
|
PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene.
|
Academic Article
|
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
|
Academic Article
|
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
|
Academic Article
|
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer.
|
Academic Article
|
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
|
Academic Article
|
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells.
|
Academic Article
|
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
|
Academic Article
|
Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion.
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
Academic Article
|
Overexpression of the µ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis.
|
Academic Article
|
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.
|
Academic Article
|
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance.
|
Academic Article
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
Academic Article
|
Role of protein kinase C ß and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
|
Academic Article
|
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
|
Academic Article
|
c-Met is a potentially new therapeutic target for treatment of human melanoma.
|
Academic Article
|
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
|
Academic Article
|
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion.
|
Academic Article
|
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
|
Academic Article
|
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
|
Academic Article
|
Personalized treatment of lung cancer.
|
Academic Article
|
Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.
|
Academic Article
|
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer.
|
Academic Article
|
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
|
Academic Article
|
Molecular and cellular biology of small cell lung cancer.
|
Academic Article
|
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.
|
Academic Article
|
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
|
Academic Article
|
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
|
Academic Article
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
Academic Article
|
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
|
Academic Article
|
Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
|
Academic Article
|
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.
|
Academic Article
|
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
|
Academic Article
|
MET as a possible target for non-small-cell lung cancer.
|
Academic Article
|
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity.
|
Academic Article
|
The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer.
|
Academic Article
|
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
|
Academic Article
|
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
|
Academic Article
|
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
|
Academic Article
|
Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.
|
Academic Article
|
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
|
Academic Article
|
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
|
Academic Article
|
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
|
Academic Article
|
AXL mediates resistance to cetuximab therapy.
|
Academic Article
|
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
|
Academic Article
|
Role played by paxillin and paxillin tyrosine phosphorylation in hepatocyte growth factor/sphingosine-1-phosphate-mediated reactive oxygen species generation, lamellipodia formation, and endothelial barrier function.
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
Academic Article
|
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
|
Academic Article
|
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
|
Academic Article
|
TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
|
Academic Article
|
Refining epidermal growth factor receptor (EGFR) -inhibition-related rash (EIRR) phenotypes with a cetuximab (C) monotherapy stage of a phase II trial for non-small cell lung cancer (NSCLC).
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
Academic Article
|
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
|
Academic Article
|
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer.
|
Academic Article
|
Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming.
|
Academic Article
|
2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76.
|
Academic Article
|
Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer.
|
Academic Article
|
Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer.
|
Academic Article
|
Targeting RLIP with CRISPR/Cas9 controls tumor growth.
|
Academic Article
|
Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM).
|
Academic Article
|
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
|
Academic Article
|
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis.
|
Academic Article
|
RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling.
|
Concept
|
Inhibitor of Growth Protein 1
|
Grant
|
Role of Paxillin in Lung Cancer
|
Grant
|
MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER
|
Grant
|
Novel Targeted Therapy in Pancreatic Cancer
|
Grant
|
Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
|
Grant
|
PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN
|